BridgeBio's acoramidis NDA accepted by FDA with PDUFA Nov 29, 2024; secured $1.25B capital; Q4 net loss $168M

BridgeBio Pharma, Inc.

2023-FY EPS reported -$3.95 revenue$9,303,000

Acoramidis NDA accepted by FDA; PDUFA Nov 29, 2024. Phase 3 met primary endpoint (Win Ratio 1.8, p<0.0001).
Secured up to $1.25B from Blue Owl and CPP Investments: $500M upfront for 5% royalty on acoramidis net sales and $450M credit facility.
Q4 2023 net loss attributable to common stockholders $168.1M ($0.96 EPS) vs $137.6M ($0.92 EPS) YoY; revenue $1.7M down from $1.9M.
Cash and cash equivalents $392.6M as of Dec 31, 2023. Full year net loss $643.2M; operating cash used $527.7M.
Partnership with Kyowa Kirin for infigratinib in Japan: $100M upfront, royalties up to high-twenties percent, milestones.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

BridgeBio Pharma, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

BridgeBio Pharma, Inc. reported recent business updates and its financial results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

BridgeBio Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-018431

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.